Agios Pharmaceuticals (AGIO) Given a $90.00 Price Target by Canaccord Genuity Analysts
Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals (NASDAQ:AGIO) in a research note published on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities research analysts also recently issued reports on AGIO. Oppenheimer reiterated a buy rating and issued a $83.00 target price on shares of Agios Pharmaceuticals in a research note on Monday. Cann reiterated a buy rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 1st. Finally, SunTrust Banks reiterated a buy rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agios Pharmaceuticals has an average rating of Buy and a consensus price target of $75.70.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $5.34 during midday trading on Tuesday, hitting $56.08. The stock had a trading volume of 571,900 shares, compared to its average volume of 510,360. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The company had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter last year, the company earned ($1.63) EPS. sell-side analysts expect that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $67.12, for a total transaction of $2,349,200.00. Following the completion of the sale, the chief executive officer now directly owns 35,000 shares in the company, valued at $2,349,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $71.09, for a total transaction of $71,090.00. Following the sale, the director now owns 84,394 shares of the company’s stock, valued at $5,999,569.46. The disclosure for this sale can be found here. Insiders have sold 166,746 shares of company stock valued at $11,344,756 over the last 90 days. Company insiders own 5.43% of the company’s stock.
A number of hedge funds have recently modified their holdings of AGIO. QS Investors LLC acquired a new stake in Agios Pharmaceuticals during the second quarter worth approximately $144,000. Cubist Systematic Strategies LLC raised its position in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $206,000. Teacher Retirement System of Texas acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $225,000. Finally, S&CO Inc. acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $227,000. Hedge funds and other institutional investors own 94.38% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.